Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas

Overview

Journal Brain Sci

Publisher MDPI

Date 2023 Feb 25

PMID 36831729

Authors

Mrinmay Kumar Mallik

Kaushik Majumdar

Shiraz Mujtaba

Affiliations

Soon will be listed here.

Abstract

During oncogenesis, alterations in driver genes called driver alterations (DAs) modulate the transcriptome, methylome and proteome through oncogenic signaling pathways. These modulatory effects of any DA may be analyzed by examining differentially expressed mRNAs (DEMs), differentially methylated genes (DMGs) and differentially expressed proteins (DEPs) between tumor samples with and without that DA. We aimed to analyze these modulations with 12 common driver genes in Isocitrate Dehydrogenase 1 wildtype glioblastomas (IDH1-W-GBs). Using Cbioportal, groups of tumor samples with and without DAs in these 12 genes were generated from the IDH1-W-GBs available from "The Cancer Genomics Atlas Firehose Legacy Study Group" (TCGA-FL-SG) on Glioblastomas (GBs). For all 12 genes, samples with and without DAs were compared for DEMs, DMGs and DEPs. We found that DAs in were unassociated with any DEM or DMG in contrast to DAs in all other drivers, which were associated with several DEMs and DMGs. This contrasting -related property of being unassociated with differential gene expression or methylation in IDH1-W-GBs was unaffected by concurrent DAs in other common drivers or by the types of DAs affecting . From the lists of DEMs and DMGs associated with some common drivers other than PTEN, enriched gene ontology terms and insights into the co-regulatory effects of these drivers on the transcriptome were obtained. The findings from this study can improve our understanding of the molecular mechanisms underlying gliomagenesis with potential therapeutic benefits.

References

Zhou Y, Lih T, Pan J, Hoti N, Dong M, Cao L . Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. J Hematol Oncol. 2020; 13(1):170. PMC: 7720039. DOI: 10.1186/s13045-020-01013-x. View

Pon J, Marra M . Driver and passenger mutations in cancer. Annu Rev Pathol. 2014; 10:25-50. DOI: 10.1146/annurev-pathol-012414-040312. View

Tomczak K, Czerwinska P, Wiznerowicz M . The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A):A68-77. PMC: 4322527. DOI: 10.5114/wo.2014.47136. View

Meacham C, Morrison S . Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501(7467):328-37. PMC: 4521623. DOI: 10.1038/nature12624. View

Benitez J, Ma J, DAntonio M, Boyer A, Camargo M, Zanca C . PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2017; 8:15223. PMC: 5437297. DOI: 10.1038/ncomms15223. View

Paczkowska M, Barenboim J, Sintupisut N, Fox N, Zhu H, Abd-Rabbo D . Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020; 11(1):735. PMC: 7002665. DOI: 10.1038/s41467-019-13983-9. View

Gubanova N, Orlova N, Dergilev A, Oparina N, Orlov Y . Glioblastoma gene network reconstruction and ontology analysis by online bioinformatics tools. J Integr Bioinform. 2021; 18(4). PMC: 8709738. DOI: 10.1515/jib-2021-0031. View

Kraboth Z, Galik B, Tompa M, Kajtar B, Urban P, Gyenesei A . DNA CpG methylation in sequential glioblastoma specimens. J Cancer Res Clin Oncol. 2020; 146(11):2885-2896. PMC: 7519911. DOI: 10.1007/s00432-020-03349-w. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

10.

Wang S, Puc J, Li J, Bruce J, Cairns P, Sidransky D . Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997; 57(19):4183-6. View

11.

Xu W, Xu M, Wang L, Zhou W, Xiang R, Shi Y . Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers. Signal Transduct Target Ther. 2019; 4:55. PMC: 6908647. DOI: 10.1038/s41392-019-0081-6. View

12.

Li J, Liang R, Song C, Xiang Y, Liu Y . Prognostic significance of epidermal growth factor receptor expression in glioma patients. Onco Targets Ther. 2018; 11:731-742. PMC: 5808691. DOI: 10.2147/OTT.S155160. View

13.

Koike N, Kassai Y, Kouta Y, Miwa H, Konishi M, Itoh N . Brorin, a novel secreted bone morphogenetic protein antagonist, promotes neurogenesis in mouse neural precursor cells. J Biol Chem. 2007; 282(21):15843-50. DOI: 10.1074/jbc.M701570200. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Das T, Andrieux G, Ahmed M, Chakraborty S . Integration of Online Omics-Data Resources for Cancer Research. Front Genet. 2020; 11:578345. PMC: 7645150. DOI: 10.3389/fgene.2020.578345. View

16.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

17.

Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

18.

Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 173(2):371-385.e18. PMC: 6029450. DOI: 10.1016/j.cell.2018.02.060. View

19.

Pettini F, Visibelli A, Cicaloni V, Iovinelli D, Spiga O . Multi-Omics Model Applied to Cancer Genetics. Int J Mol Sci. 2021; 22(11). PMC: 8199287. DOI: 10.3390/ijms22115751. View

20.

Yu K, Zhang C, Berry G, Altman R, Re C, Rubin D . Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun. 2016; 7:12474. PMC: 4990706. DOI: 10.1038/ncomms12474. View